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A new simian-human immunodeﬁciency virus (SHIV), carrying env from an uncloned HIV-1 subtype C
clinical isolate (97ZA012), was generated through intracellular homologous recombination, a DNA
repair mechanism of the host cell. PCR fragments ampliﬁed from an existing SHIV plasmid (a 7-kb
fragment from the 50 end and a 1.5-kb fragment from the 30 end) and a 4-kb fragment ampliﬁed from
97ZA012 cDNA containing env were co-transfected to human lymphoid cells. The resulting recombi-
nant was subjected to serial passage in rhesus peripheral blood mononuclear cells (RhPBMCs).
The resulting SHIV 97ZA012 was replication competent in RhPBMCs and monkey alveolar macrophages,
and possessed CCR5 preference as an entry co-receptor. Experimental infection of rhesus macaques
with SHIV 97ZA012 caused high titers of plasma viremia and a transient but profound depletion of
CD4þ T lymphocytes in the lung. Animal-to-animal passage was shown to be a promising measure for
further adaptation of the virus in monkeys.
& 2012 Elsevier Inc. All rights reserved.Introduction
Human immunodeﬁciency virus (HIV) infections have been a
major global public health issue since their initial recognition in
the 1980s. Globally, approximately 33 million individuals are
living with HIV, 1.8 million people die of HIV-related complica-
tions, and 2.6 million people newly acquired the virus in 2009
(UNAIDS, 2010). Establishment of effective preventive measures
is urgently needed to control the epidemic.
Extensive genomic diversity is a characteristic trait of HIV. HIV
type 1 (HIV-1), the major genotype of the virus, comprises four
subgroups: M, N, O, and P. Subgroup M further comprises
numerous subtypes and circulating recombinant forms (CRFs),ll rights reserved.
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iura),which are recombinant viruses among subtypes. Among the
subtypes, subtype C plays a leading role in the epidemic, account-
ing for nearly 50% of global HIV infections (Hemelaar et al., 2011).
Greater numbers of viral particles are detected in the vaginal
secretions of pregnant individuals infected with subtype C than
from persons infected with subtypes A or D (John-Stewart et al.,
2005), potentially making subtype C more transmissible than
others and rendering it predominant in the current epidemic.
A compact V1/V2 loop and threonine at 316 located in the V3 loop
of Env, distinct features shared by many subtype C isolates, may
contribute to preferential replication of these viruses in the
genital tract (Walter et al., 2009).
The humoral immune reaction directed against subtype C virus
is unequal to that directed against subtype B virus. Virus-
neutralizing antibodies mounted in individuals infected with
subtype C are directed against the alpha-2 helix in the Env C3
region. This region is rarely immunogenic in subtype B virus
infection (Moore et al., 2008), indicating a conformational differ-
ence in Env between these subtypes. The development of a
tractable animal model for subtype C is thus necessary to
establish a strategy for effective induction of neutralizing anti-
bodies directed against the protein of this particular subtype.
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derived from subtype C would be an especially vital tool because
it would allow for evaluation of the effectiveness of vaccine-
induced immunity in the context of virus infection in vivo.
However, only a few subtype C SHIVs are available, and none
reproducibly replicates to high titers and induces disease in
monkeys. In addition, limited numbers of SHIVs utilize the CCR5
molecule as an entry co-receptor. The scarcity of available SHIV
strains is attributed to the difﬁculty in generating an infectious
chimeric virus. SHIVs have been generated through recombinant
DNA techniques involving implantation of a chunk of genes, such
as tat, rev, vpu, and env, from the molecular clone of parental HIV-
1 into the backbone of the SIV239 molecular clone. This method
does not always lead to successful generation of infectious SHIV.
Two presumable reasons may explain this difﬁculty: (1) incom-
patibility of a particular clone from the parental HIV-1 swarm
with the SIV backbone and (2) inadequate employment of ‘‘break-
points,’’ sites of recombination, for the given parental clones of
HIV-1 and SIV. The generation of SHIVs by the conventional
technique (i.e., recombination of HIV-1 genes from a molecular
clone veriﬁed to be infectious to human cells with an SIV back-
bone at breakpoints that are reasonably assumed to be appro-
priate) may represent a major bottleneck for the development of
new SHIV strains.
Intracellular homologous recombination (IHR) is a cellular
mechanism for the restoration of DNA double-strand breaks.
It also takes place when exogenously introduced DNA fragments
share ‘‘homologous sequences’’ (Srinivasan et al., 1989).
The mechanism has been attributed to the generation of infectious
HIV-1 particles from cell lines carrying multiple defective pro-
virus genomes (Inoue et al., 1991). IHR also causes generation of
infectious HIV-1 through co-transfection of truncated viral cDNA
clones into the cells (Kalyanaraman et al., 1988; Srinivasan et al.,
1989) or through recombination between exogenous sequences
and integrated chromosomal HIV sequences (Clavel et al., 1989;
Srinivasan et al., 1989). It is then utilized as a measure to readily
generate recombinant HIV-1 (Cheng-Mayer et al., 1990; Hertogs
et al., 1998; Kellam and Larder, 1994).
We reasoned that generation of SHIV through IHR could
circumnavigate the above-mentioned issues and accelerate the
process as follows: (1) DNA fragments prepared by polymeraseFig. 1. Schematic representation of HIV-1/SHIV genome organizations and PCR fragme
Open boxes represent genes derived from HIV-1. SHIV KS661, existing SHIV, carries t
fragments; Fragments I and II-a/II-b were ampliﬁed using plasmid DNA of SHIV KS661 a
as a template. Arrows represent PCR primers whose identiﬁers are depicted in the ﬁguchain reaction (PCR) with cDNA from an uncloned HIV-1 genome
would provide a continuum of heterogeneous sequences that
potentially contain competent clone(s) in the context of infection
in monkey cells in vitro and monkeys in vivo when combined with
an SIV backbone, and (2) random occurrence of IHR within ‘‘homo-
logous sequences’’ would likely produce multiple SHIV genomes
with breakpoints at various sites, increasing the chance for emer-
gence of a virus with favorable ﬁtness. In addition, co-transfection
of DNA fragments into cells susceptible to viral infection would
subject the generated recombinant virus to multi-round replication,
causing selection/evolution of a replication-competent virus. Based
on this reasoning, we embarked on IHR-mediated generation of
SHIV to investigate the utility of these potential advantages.Results
Generation of recombinant virus through IHR
To generate a novel SHIV carrying the env gene derived from a
clinical isolate of subtype C HIV-1 through IHR, we prepared three
DNA fragments by PCR as depicted in Fig. 1. Approximately
1100 bps of overlapping sequence (where IHR was expected to
take place) were shared by Fragments I and III, 1400 bps were
shared by Fragments II-a and III, and 1200 bps were shared by
Fragments II-b and III (Fig. 1).
Although we envisioned that recombination between the
two DNA fragments could theoretically take place at any base
within these overlaps, potentially resulting in generation of multi-
ple sets of recombinant genomes, only replication-competent
recombinant(s) would emerge as representative following trans-
fection with these fragments into susceptible cells for lentiviral
replication and multi-round replication cycles. To test this hypoth-
esis, mixtures of Fragments I, II-a, and III (Transfection #1)
or Fragments I, II-b, and III (Transfection #2), 0.2 mg of each
DNA preparation, were co-transfected to human T-lymphoid cell
line C8166-CCR5 cells. The cultures were maintained for 3 weeks
to monitor emergence of recombinant virus by microscopic obser-
vation because the parental HIV-1 97ZA012, which contributed the
env gene to the transfection, was known to induce syncytia in the
cells (data not shown). Transfection #1 produced syncytia on daynts employed for co-transfection. Filled boxes represent genes derived from SIV.
at, rev, vpu, and env genes from subtype B HIV-1 89.6. Broad lines represent PCR
s a template. Fragment III was ampliﬁed from cDNA of the HIV-1 97ZA012 genome
re.
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15. A small portion of each culture was collected on the day of
syncytia emergence and co-cultivated with uninfected C8166-
CCR5 cells to determine whether the syncytia would spread. Both
initiated robust syncytia formation within 24 h post co-cultivation,
suggesting generation of a recombinant virus capable of replicating
in C8166-CCR5 cells. Culture supernatants collected at 3 days post-
co-culture, viz. 17 days post-Transfection #1 and 18 days post-
Transfection #2, were combined and used as starting material for
in vitro selection/adaptation.
In vitro passage of the recombinant virus
Because we aimed to generate a new SHIV strain to be used in
a macaque model, which requires a virus with the capacity to
replicate to a high titer, we ﬁrst subjected the ‘‘syncytium-
inducing agent,’’ which emerged through IHR, to sequential
passage in rhesus macaque PBMCs (RhPBMC). We envisioned
that a certain population of the recombinant carrying a suitable
genotype from the parental virus swarm and appropriate recom-
bination breakpoints might outgrow and/or evolve through the
passage. Newly generated recombinant viruses are known in
general to be less replication competent, especially in RhPBMCs.
Such viruses have replicated better when inoculated into CD4þFig. 2. Passage of the recombinant virus through RhPBMCs. Recombinant virus that eme
through RhPBMCs (A–E). A small amount of supernatant was collected from each cultu
activities were represented as radioactive counts per minute (cpm) induced by 1 ml c
Passages #1–3 (A–C), and whole RhPBMCs were utilized for Passages #4 and #5 (D and
culture, except from Passage #2 to #3, in which the mixture of cells and supernatantcell-enriched RhPBMCs by deletion of CD8þ cells (Chen et al.,
2000; Kamada et al., 2006). Although the viral agent was robustly
replicating in human C8166-CCR5 cells, we followed the previous
observations and inoculated 100 ml ﬁltered culture supernatant of
the cells into 2106 rhesus macaque CD4þ cell-enriched RhPBMCs
(Passage #1). Virus replication was monitored by virion-associated
reverse transcriptase (RT) activity released in the culture super-
natant (Fig. 2).
Passage #1 revealed that the virus indeed replicated in CD4þ
cell-enriched RhPBMCs (Fig. 2A). The virus replicated to an initial
peak of RT activity on day 3 with 2000 cpm/ml supernatant
equivalent, and replication was then reduced somewhat on day
4 (1250 cpm), likely because of the addition of fresh CD4þ
cell-enriched PBMCs. Replication increased again to 2170 cpm
on day 5, the highest RT activity in this passage. The RT activity
was maintained at a high level during the subsequent 2 days
(1900–2000 cpm), then declined rapidly on day 8. Cryopreserved
culture supernatant (50 ml) collected from day 5 of Passage #1
was inoculated to 2106 newly prepared CD4þ cell-enriched
RhPBMCs to conﬁrm the observed replication property of the
virus (Passage #2). Although replication in Passage #2 took longer
than that in Passage #1, the Passage #2 virus also replicated to a
high titer, 2180 cpm/ml supernatant equivalent on day 8, followed
by a sharp decline on day 9 (1250 cpm; Fig. 2B).rged from C8166-CCR5 cells co-transfected with PCR fragments was serially passed
re daily, and virion-associated reverse transcriptase (RT) activity was assessed. RT
ulture supernatant equivalent. CD4þ cell-enriched RhPBMCs were employed for
E). Filtered culture supernatant was used to pass virus from existing culture to new
was inoculated to freshly prepared cells.
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cell-enriched RhPBMCs, we next examined whether the virus
could replicate in unmanipulated RhPBMCs, a cell preparation
without enrichment of CD4þ cells, by taking a small portion of
the ongoing culture on day 8 and co-cultivating it with fresh
whole RhPBMCs (Passage #3). For this experiment, we monitored
the RT activity of the culture supernatant from Passage #2 daily
and decided to set up Passage #3 because of a substantial increase
in RT activity on day 8. Passage #3 resulted in robust virus
replication that reached 5,250 cpm/ml supernatant equivalent on
day 7, then declined during the following days, suggesting that
it possessed replication capacity in unmanipulated RhPBMCs
(Fig. 2C). To determine whether we could reproduce this observa-
tion in a more rigorous setting, culture supernatant without
cells, collected on day 7 from Passage #3, was inoculated into
whole RhPBMCs newly prepared from normal rhesus macaques
(Passage #4). The virus replicated robustly to a high titer, reach-
ing 1850 cpm/ml supernatant equivalent on day 5, followed
by a rapid decline (Fig. 2D). To conﬁrm the observation, we inocu-
lated supernatant collected on day 5 of Passage #4 into another
RhPBMC preparation without manipulation a second time
(Passage #5). The virus reproducibly replicated in primary monkey
cells, with a peak of RT activity on day 5 post-infection (2280 cpm;Fig. 3. Genomic organization of SHIV 97ZA012. (A) Breakpoints in SHIV 97ZA012 wer
(black) as references. Schematic SHIV genome organization was aligned to similarity plo
gene portion identiﬁed in (A), between nt 6429 and 8325 (in HIV-1 HXB2) and d
corresponding sequence of the reference virus isolates. The phylogenetic tree was genFig. 2E). We concluded that a new recombinant virus capable
of replicating in RhPBMCs was generated/evolved through IHR/
in vitro passage. We designated the culture supernatant collected
on day 5 from Passage #5 as SHIV 97ZA012 and subjected it to
further characterization.
Genomic organization of SHIV 97ZA012
To elucidate the genomic organization of SHIV 97ZA012, the nt
sequence was determined on cDNA that was reverse-transcribed
from virion-associated viral genomic RNA prepared from the culture
supernatant. The obtained sequence was compared with those of
SHIV KS661 and HIV-1 97ZA012 (Fig. 3). Genomic analysis revealed
that the 50 and 30 breakpoints were at the 282nd nt of env gp120,
upstream of the V1/V2 loop, and the 756th nt of the env gp41
cytoplasmic domain, respectively (Fig. 3A). The breakpoints that
gave rise to replication-competent virus were not necessarily at the
interface of genes juxtaposed to each other. This is also the case in
many CRFs of HIV-1, examples of naturally occurring recombinants
(Carr et al., 2001; Guimaraes et al., 2008; Koulinska et al., 2001;
Perez et al., 2006; Piyasirisilp et al., 2000).
SimPlot (Lole et al., 1999) analysis revealed that the genomic
fragment derived from HIV-1 97ZA012 did not completely matche analyzed by the SimPlot program with SHIV KS661 (gray) and HIV-1 97ZA012
t for a visual purpose. (B) Phylogenetic analysis of SHIV 97ZA012 env portion. The
erived from HIV-1 97ZA012, was subjected to phylogenetic analysis with the
erated by the neighbor-joining method.
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AF286227). To ascertain that the recombinant virus indeed carries
the env sequence derived from HIV-1 97ZA012, we conducted a
phylogenetic analysis of the sequence with the corresponding
region of HIV-1 strains belonging to subtype B or C, including the
registered sequence of 97ZA012 (Fig. 3B). The supposed 97ZA012-
derived sequence naturally formed a subcluster with the regis-
tered sequence and was positioned in the cluster of subtype C
strains in the phylogenetic tree. We concluded that the observed
difference in sequences between SHIV 97ZA012 and the regis-
tered HIV-1 97ZA012 was within the extent of quasispecies of a
single isolate.Replication properties of SHIV 97ZA012 in C8166-CCR5 cells
and RhPBMCs
To characterize the replication properties of SHIV 97ZA012, we
inoculated the virus into human C8166-CCR5 cells and RhPBMCs.
Because HIV-1 is unable to replicate in monkey cells, the relative
replication capability of the newly generated virus to the parental
HIV-1 97ZA012 was assessed in C8166-CCR5 cells. SHIV KS661,
which provided the backbone for SHIV 97ZA012, was also
examined. In RhPBMCs, replication of SHIV 97ZA012 was com-
pared with that of SIV239, the most widely used SIV. The viruses
were normalized to an infectious unit (multiplicity of infection
[MOI]¼0.01 or 0.1 median tissue culture infective dose [TCID50/
cell]) and inoculated into these cells. Replication of the viruses
was monitored by virion-associated RT activity in the culture
supernatant (Fig. 4). Because C8166-CCR5 cells were highly
susceptible to HIV-1/SIV and progressed to cell death, infections
at a higher multiplicity (MOI¼0.1) resulted in lower peak RT
activities compared with those at a lower multiplicity (Fig. 4A).
Regardless of multiplicity, SHIV 97ZA012 exhibited a slower
replication kinetic compared with that of the parental HIV-1Fig. 4. Replication of SHIV 97ZA012 in C8166-CCR5 cells (A) and RhPBMCs (B). The
replication property of SHIV 97ZA012 in these cells was compared with those of
HIV-1 97ZA012, SHIV KS661 (A) and SIV239 (B). The viruses were normalized by
the infectious unit (MOI¼0.01 and 0. 1 TCID50/cell) and spinoculated to these
cells at 1200 g for 60 min. Gray symbols/lines represent virus replication at
MOI¼0.01, and black symbols/lines represent virus replication at MOI.¼0.1.
Culture supernatant was collected daily, and virion-associated reverse transcrip-
tase activities were assessed.97ZA012, likely due to the chimeric structure of the virus
(Li et al., 1992; Shibata et al., 1991) or to the result of adaptation
to monkey cells. SHIV KS661 also exhibited faster replication
kinetics compared with SHIV 97ZA012.
While SHIV 97ZA012 exhibited a slower replication proﬁle
compared with the reference viruses in C8166-CCR5 cells, repli-
cation of SHIV 97ZA012 in RhPBMCs was comparable with that of
SIV239 (Fig. 4B). Infection at a MOI¼0.01 resulted in somewhat
more production of progeny in SIV239 than in SHIV 97ZA012
during the ﬁrst 3 days. When the experiment was set up at a
MOI¼0.1, SIV239 produced markedly more progeny than did
SHIV 97ZA012 during the ﬁrst 3 days of infection, while SHIV
97ZA012 replicated to higher titers than did SIV239 at day 4 and
thereafter. To estimate the total production of progeny virus
during the observation period, the areas under the curve (AUC)
of each virus were compared. The AUC of SHIV 97ZA012 was
approximately 1.5-fold greater than that of SIV (data not shown).
Based on these data, we concluded that SHIV 97ZA012 is as
replication competent as SIV239 in rhesus macaque PBMCs.
Co-receptor preference of SHIV 97ZA012
The parental HIV-1 97ZA012 strain reportedly utilizes CCR5 as
an entry co-receptor (Broder and Jones-Trower, 1999). The chimeric
structure of gp120 carried by SHIV 97ZA012 (between KS661,
which was originally derived from HIV-1 89.6, and 97ZA012) and
uncertainty of the co-receptor preference of 97ZA012 Env in the
context of the SHIV/macaque cell system prompted us to subject
SHIV 97ZA012, along with control viruses, to a co-receptor usage
assay. Each virus, normalized by an infectious unit, was inoculated
to RhPBMCs in the presence of 5 mM AMD3100 (a small-molecule
CXCR4 inhibitor), AD101 (a small-molecule CCR5 inhibitor), or both.
Virus replication was monitored for 7 days by virion-associated RT
activity release in the culture supernatant (Fig. 5). SIV239, which
has been established as a CCR5-utilizing virus, replicated to a high
titer in the absence of any inhibitor (Fig. 5A). AMD3100 had little
impact on the replication of the virus, as described previously
(Zhang et al., 2000). In the presence of AD101 or both inhibitors,
however, replication of SIV239 was substantially impaired. In
contrast, SHIV KS661, which has been reported to predominantly
utilize CXCR4 as an entry co-receptor (Matsuda et al., 2010),
exhibited a replication proﬁle opposite to that of SIV239: no
impairment of replication in the presence of AD101, but remarkably
delayed replication in the presence of AMD3100, and complete
suppression in the presence of both inhibitors (Fig. 5B). When
control viruses exhibited the replication proﬁles described above,
SHIV 97ZA012 exhibited a replication proﬁle similar to that of
SIV239: no impact on replication in the presence of AMD3100, but
complete suppression when AD101 was present in the culture
(Fig. 5C). Based on these results, we concluded that SHIV 97ZA012
is a CCR5-utilizing virus, as is the parental HIV-1 97ZA012 in
human cells.
Replication of SHIV 97ZA012 in macrophages
Many CCR5-utilizing HIV-1 strains replicate in monocyte-
derived macrophages, which is a biological property called
‘‘macrophage tropism.’’ Macrophage tropism has been shown to
be associated with viral neurotropism (Gorry et al., 2001), a
subject to be investigated in non-human primate AIDS models.
To clarify the biological property of the virus in macrophages,
SHIV 97ZA012, along with macrophage-tropic and non-
macrophage-tropic viruses, normalized by RT activity was inocu-
lated to rhesus macaque primary alveolar macrophage (RhAM)
cultures prepared from three uninfected animals. Virus replica-
tion was monitored by virion-associated RT activity released in
Fig. 6. Replication of SHIV 97ZA012 in primary rhesus alveolar macrophages
(RhAMs). SHIV 97ZA012, along with macrophage-tropic SIV316 and SHIV l3-3 and
non-macrophage-tropic SIV239, was inoculated into primary RhAMs, and its
replication was monitored for 3 weeks. RhAMs were prepared from three animals
independently (A–C). Virus replication was assessed by reverse transcriptase
activity in the culture supernatant.
Fig. 5. Co-receptor usage of SHIV 97ZA012. SHIV 97ZA012, along with CCR5-tropic
SIV239 and predominantly CXCR4-tropic SHIV KS661, was inoculated into
RhPBMCs in the presence of small-molecule co-receptor inhibitor(s) (5 mM), and
replication was assessed by reverse transcriptase activity in the culture supernatant for
7 days. The following compounds were utilized as co-receptor inhibitors: AMD3100 for
anti-CXCR4 inhibitor and AD101 for anti-CCR5 inhibitor, which was kindly provided by
Dr. Julie Strizki, Schering-Plough Research Institute, Kenilworth, NJ.
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consistent replication proﬁles among cell cultures prepared from
different individuals (Fig. 6A–C). SIV316, a macrophage-tropic
variant of SIV239 (Desrosiers et al., 1991), replicated to the highest
titers among the viruses, reaching a peak around days 7–9 post-
infection (2000–2500 cpm/ml). SHIV l3-3, a macrophage-tropic
SHIV (Igarashi et al., 2007), exhibited a delayed replication proﬁle
and reached titers of 41000 cpm/ml after 17 days post-infection.
In contrast, SIV239, which is reportedly incapable of replicating in
cells of this type (Mori et al., 1993), produced no measurable RT
activity in the supernatant during the observation period. Under
this condition, SHIV 97ZA012 replicated productively, although not
as robustly as SIV316 or SHIV l3-3, and reached peak virus
replication on day 9 post-infection (400–600 cpm/ml). Based on
these results, we concluded that SHIV 97ZA012 is macrophage
tropic.
Experimental infection of rhesus macaques with SHIV 97ZA012
Biological properties of the newly generated SHIV 97ZA012
revealed in the study, including CCR5 utilization, a robustreplication proﬁle in RhPBMCs, and infectiousness in primary
macrophages, justiﬁed experimental infection of monkeys with
the virus. Prior to the infection, we prepared an ample volume of
animal challenge stock of the virus by inoculating SHIV 97ZA012
seed to RhPBMCs. Culture supernatant was collected daily and
assessed for virus replication by RT activity. Fractions of culture
supernatant collected on days 8 and 9 that exhibited the highest RT
activities (2450 and 2550 cpm/ml supernatant equivalent) were
combined, ﬁltered through a 0.45-mm membrane, divided into
aliquots designated SHIV 97ZA012 animal challenge stock, and
stored in liquid nitrogen. The infectious titer of the virus stock was
1.51104 TCID50/ml, and retention of its preference for CCR5 as an
entry co-receptor was veriﬁed (data not shown).
The animal challenge stock of SHIV 97ZA012, 1105 TCID50,
was intravenously inoculated into each of three rhesus macaques.
Virus replication was monitored by viral RNA load in plasma
samples that were collected periodically (Fig. 7). The virus
replicated to substantially high titers in all three animals, reach-
ing an initial peak of 1.03108 copies/ml for MM533, 4.52106
copies/ml for MM535, and 1.83108 copies/ml for MM536 at
week 1.1 (day 8) post-inoculation (Fig. 7A). After the initial peak,
Fig. 7. Experimental infection of rhesus macaques with SHIV 97ZA012. 1
105 TCID50 SHIV 97ZA012 animal challenge stock was intravenously inoculated
into three rhesus macaques, MM533, MM535, and MM536. Their plasma viral
burdens (A), circulating CD4þ T lymphocytes (B), and CD4þ T cells in the alveolar
space (C) were monitored periodically. Lymph node cells and whole blood
collected from MM535 and MM536 at week 10.7 were transferred to MM554
(A–C).
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remained at approximately 1106 copies/ml between weeks
3 and 5. One of the animals, MM533, was found to be lethargic
and subsequently died at week 4. The cause of death was not
related to primate lentivirus infection. The plasma viral burdens
of the remaining two animals gradually declined from week
6 onward, resulting in barely detectable levels at week 20 (650
copies/ml for MM535 and 740 copies/ml for MM536).
(Fig. 7B). Although all three animals experienced a transient
decrease in cell numbers, the cell numbers promptly rebounded
thereafter and basically stabilized after week 8 for MM535 and
week 6 for MM536.
SIV and HIV-1 preferentially replicate at an ‘‘effector site,’’ such
as the mucosal tissues of the genital organs, lung, and gastro-
intestinal tract, where CCR5-positive effector memory CD4þ T
lymphocytes, the primary viral target cells, predominantly reside.
Here, they cause substantial depletion of cells during the acute
phase of infection (Brenchley et al., 2004; Okoye et al., 2007;
Veazey et al., 1998; Veazey et al., 2003). Because SHIV 97ZA012
utilizes the CCR5 molecule as an entry coreceptor, it was envi-
saged that the virus depletes effector memory CD4þ T lympho-
cytes as do SIV and HIV-1. We examined the ﬂuctuation in CD4þ
T lymphocytes in the pulmonary space of SHIV 97ZA012-infectedanimals as the representative effector site because the procedure
causes the least severe insult to animals, allowing us to conduct
frequent monitoring. It is known that SIV239 infection results a
substantial depletion of pulmonary CD4þ T cells in infected
rhesus macaques, along with depletion of the cells in the gastro-
intestinal tract (Okoye et al., 2007). In contrast to the cells in
circulation, CD4þ T cells in the alveolar space exhibited a
substantial decline during the acute phase of SHIV 97ZA012
infection (Fig. 7C). The percentages of cells dropped from 48.5%,
52.1%, and 44.7% for MM533, MM535, and MM536, respectively,
on day 0 to 6.3% for MM533 at week 2.7, 16.8% for MM535 at
week 5, and 2.6% for MM536 at week 2.7. The alveolar CD4þ T
lymphocytes remained at low levels in the animals until week 11,
then gradually increased toward pre-infection levels. Based on the
results described above, it was concluded that SHIV 97ZA012
robustly replicated during the acute phase of infection, causing
remarkable reduction of CD4þ T cells in the alveolar space.
However, the animals eventually controlled the virus replication.
SHIV 97ZA012 thus appeared to be less likely to cause disease in
monkeys.
Multiple reports on the evolution of primate lentivirus through
animal-to-animal passage have shown that initially less-
efﬁciently replicating and non-pathogenic viruses transform to
replication-competent and highly pathogenic viruses (Joag et al.,
1996; Reimann et al., 1996a; Sharma et al., 1992). We applied this
strategy to SHIV 97ZA012. At week 10.7, the axillary lymph nodes
were collected from animals MM535 and MM536. Cells prepared
from the lymph nodes from both animals, 5108 cells in total,
were resuspended with 10 ml anti-coagulated whole blood col-
lected simultaneously from these monkeys. The resuspension was
intravenously transferred to another rhesus macaque, MM554.
The virological and immunological parameters of the recipient
animal were monitored as described above. The virus induced
viremia with an initial peak of 4.2108 copies/ml at week 1.6,
followed by a gradual decrease until week 8, then was maintained
at approximately 3–4 105 copies/ml for 4 weeks (Fig. 7A).
Although the plasma viral burden of MM554 declined after the
initial peak, its titer was constantly higher than those inoculated
with the original animal challenge stock of SHIV 97ZA012,
indicating likely improvement in virus replication. Numbers of
circulating CD4þ T lymphocytes in MM554 did not change sub-
stantially compared with the other animals (Fig. 7B). MM554
manifested a more substantial reduction in alveolar CD4þ T cells
than did the other three animals (Fig. 7C). The percentage of CD4þ
T lymphocytes dropped from 61% at day 0 to 2.8% at week 3, and
further declined to 1.4% at week 5. The cell numbers remained low
until week 7 and started to recover thereafter. Based on these
results, we concluded that animal-to-animal passage appears to
have made SHIV 97ZA012 more ﬁt to replicate in macaque
monkeys, warranting improvement by further passage.Discussion
In this study, we successfully generated a new SHIV strain
carrying Env derived from an HIV-1 subtype C primary isolate,
HIV-1 97ZA012, utilizing IHR. The presumable advantages of the
method employed in the current study over conventional methods
utilizing existing/newly generated restriction sites are random
utilization of breakpoints within homologous sequences and selec-
tion of replication-competent recombinants through multi-round
replication in the susceptible cells. These factors may have con-
tributed to the generation of the new SHIV in the current study.
Initially, SHIVs have been generated through recombination of
infectious molecular clones of SIV and HIV-1 (Shibata et al., 1991
#143; Li et al., 1992 #141; Luciw et al., 1995 #152; Reimann
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clone(s) was thus a prerequisite for the generation of SHIV. The
SHIVs generated in the abovementioned manner generally exhib-
ited insubstantial replication proﬁles in vitro and in vivo (Shibata
et al., 1991 #143; Li et al., 1992 #141; Sakuragi et al., 1992 #151;
Luciw et al., 1995 #152; Reimann et al., 1996b #153}. Plasmid
clones carrying open reading frames that were derived from PCR
fragments ampliﬁed from HIV-1 provirus were subsequently
employed as the source of HIV-1 genes, instead of DNA fragments
excised from full-length molecular clones (Chen et al., 2000 #1;
Kuwata et al., 2002 #135}. Kuwata et al. generated 30 SHIV clones
representing Env protein from three independent isolates of HIV-1
from the initial exertion to generate SHIV strains representing
six separate HIV-1 isolates. Of 30 clones, three were infectious to
human cells, and only one productively replicated in monkey
PBMCs but exhibited only modest replication in vivo {Kuwata et
al., 2002 #135}. Hence, generation of replication-competent
SHIVs by the conventional method is inefﬁcient.
In contrast, the IHR-mediated method described in the current
study generated replication-competent SHIV 97ZA012 without
the requirement for an infectious molecular clone of the parental
HIV-1, exploration of appropriate restriction sites, or examination
of each plasmid clone for infectivity. This was performed in a
considerably shorter time frame in our experience, saving several
months compared with conventional methods. However, one
would argue that IHR-mediated generation of SHIV does not
allow for a detailed genetic analysis, such as mutagenesis of
particular gene(s), because of the virus being ‘‘swarm.’’ While this
is undeniable, the vast majority of currently available replication-
competent SHIVs are resultants of evolution through animal-to-
animal passage and exist as quasispecies (Joag et al., 1996 #49;
Reimann et al., 1996a #52; Igarashi et al., 1999 #156; Harouse et
al., 2001 #154; Song et al., 2006 #158; Nishimura et al., 2010
#157}. A molecular-cloned virus representing the properties of
the swarm is attainable by introduction of consensus sequences
to a molecular clone, if necessary.
Co-transfection of genome fragments into C8166-CCR5 cells
appears to have generated multiple recombinant viruses with
distinct breakpoints and/or env genes. Following short-term
propagation of the virus that emerged after co-transfection, viral
genomic RNA from culture supernatant was subjected to sequen-
cing without a cloning step. We were unable to determine the
sequence within the overlaps between Fragments I and III or II-a/
b and III (Fig. 1) because of multiple sequence peaks at each
location, suggesting the existence of multiple DNA templates
(data not shown). The mixture of recombinants was substantially
‘‘puriﬁed’’ through serial passages in RhPBMCs (Fig. 2), allowing
us to determine breakpoints (Fig. 3). This observation supports
the relevance of the concept employed in the current study; that
is, selection of replication-competent recombinants through
multi-round replication.
The selected replication-competent recombinant virus pos-
sesses breakpoints within the env gene, resulting in a ‘‘mosaic’’
env structure. Because primate lentiviruses encode multiple genes
in different reading frames in a stratiﬁed fashion, tat and rev
genes also became mosaic. The mosaic tat, rev, and env genes are
not uncommon among circulating recombinant forms of HIV-1
(Carr et al., 2001; Koulinska et al., 2001; Ng et al., 2012; Su et al.,
2000; Yamaguchi et al., 2008), although these breakpoints are less
likely to be employed in rational construction of SHIVs.
SHIV 97ZA012 replicated to a titer comparable with that of
SIV239 in RhPBMCs, and the observed trend was unaffected by
the reduction in MOI (from 0. 1 to 0.01 in Fig. 4B), an indication of
the replication competence of SHIV 97ZA012 in the cells. In
addition, SHIV 97ZA012 exhibited productive replication in rhe-
sus primary alveolar macrophages, although not as robust as thatof SIV316 (Fig. 6). In our experience, not every ‘‘macrophage-
tropic’’ virus replicates in alveolar macrophages. While SIV 251
and SIVsmE543 have been reported to be macrophage-tropic in
monocyte-derived macrophages (Hirsch et al., 1997; Miller et al.,
1998), they did not replicate in alveolar macrophages (Igarashi
et al., unpublished). Alveolar macrophages of human or rhesus
macaque express miniscule amounts of CD4 and CCR5 (Mori et al.,
2000; Worgall et al., 1999). Therefore, SHIV 97ZA012 may be able
to gain entry to cells expressing minimal numbers of receptors/
coreceptors, as is SIV316 (Puffer et al., 2002). Whether ‘‘CD4-
independence’’ is a property shared by many subtype-C Env or is
speciﬁc to 97ZA012 or whether a ‘‘mosaic’’ Env protein between
HIV-1 89.6 and 97ZA012 caused this notable property remains to
be investigated.
This study also presents potential shortcomings of IHR to be
resolved in the future. The ﬁrst drawback is that only a limited
variety of Env may function in the C8166-CCR5 cells utilized in the
current study, resulting in generation of SHIVs reﬂecting this
potential restriction. Prior to the current study, we inoculated nine
primary isolates of HIV-1 subtype C obtained from the National
Institutes of Health (NIH) AIDS Research & Reference Reagent
Program into the cells and found that seven of them replicated
in the cells with syncytia (data not shown). Cells susceptible to a
broad range of HIV-1 primary isolates should be utilized in the
future. The second shortcoming is the relatively long (2-week)
‘‘incubation phase’’ following co-transfection. The low frequency
of recombination events and less-efﬁcient DNA transfection may
have been responsible for the elongated incubation period.
Upregulation of IHR through certain means, such as overexpres-
sion of Rad51 (Vispe et al., 1998) (an enzyme that plays an
important role in IHR) prior to co-transfection of viral cDNA
fragments or utilization of certain cells that are shown to exhibit
elevated IHR activity (e.g., breast cancer cells (Mao et al., 2009))
could augment the efﬁciency of recombination. To achieve
higher transfection efﬁciency, utilization of well-established
and highly transfectable cells, such as 293 T (formerly
293tsA1609neo) cells (DuBridge et al., 1987), followed by co-
cultivation with cells susceptible to virus replication, such as
PBMCs, should be explored.
We were able to detect syncytia formation in the culture
transfected with DNA fragments only after 2 weeks. Once syncytia
emerged, however, the virus replicated productively in C8166-CCR5
cells and subsequently in RhPBMCs enriched with CD4þ cells and
unmanipulated RhPBMCs through a passage in RhPBMCs. SHIV
97ZA012 evolved to be replication competent in RhPBMCs and
infectious to RhAMs. The virus may have been replication competent
in monkey cells from the beginning. Although HIV-1 97ZA012, which
contributed env to SHIV 97ZA012, may have been predisposed to be
adequate as a parental virus for generation of SHIV, we have the
impression that the method we employed in this study generated a
pool of recombinants and selected suitable one(s) through in vitro
passage. As mentioned above, the recombinant virus that initially
emerged was a mixture, and the ﬁnal genotype(s) was selected and/
or evolved through in vitro passage. The only traits of HIV-1 97ZA012
of which we were aware were its replication competence in human
PBMCs and its preference for CCR5 as an entry co-receptor to the
cells (data not shown).
SHIV 97ZA012 reproducibly replicated to high titers in vivo
with a major reduction in pulmonary CD4þ T cells during the
acute phase of infection. Considering the paucity of available SHIV
strains carrying subtype C Env and a CCR5 co-receptor preference
in the ﬁeld, the virus generated in the current study would
immediately ﬁt the interest for evaluation of anti-subtype C
vaccine candidates. The virus would be especially useful when
the efﬁcacy of antiviral interventions is judged by reduction of the
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CD4þ T lymphocytes in the effector sites.
Although we successfully generated an SHIV strain competent
in tissue culture, the generation of a proﬁcient virus in vivo
remains arduous. Indeed, SHIV 97ZA012 replicated to substan-
tially high titers during the acute phase of infection. However, the
plasma viral load waned with time, as did SHIV strains generated
previously. Animal-to-animal passage would augment its replica-
tion in vivo, as we attempted in this study.
This study has demonstrated the versatility of IHR-mediated
generation of SHIV. The method enables utilization of a PCR
fragment ampliﬁed from uncloned virus as a source for SHIV.
This method can be further extended to generate SHIV strains
with sequences ampliﬁed from clinical samples, such as patient
plasma, to strengthen the panel of challenging viruses for evalua-
tion of an anti-HIV vaccine.Conclusions
By employing IHR, a replication-competent SHIV carrying Env
derived from a CCR5-tropic, subtype C HIV-1 97ZA012 strain was
generated.Materials and methods
Cells
C8166-CCR5 cells from a human T-lymphotropic virus type-1-
transformed human T-lymphoid cell line that was transduced to
express human CCR5 and established as described previously
(Soda et al., 1999) were generously provided by Dr. Hiroo
Hoshino, Gunma University, Japan. The cells were cultured in
Roswell Park Memorial Institute 1640 medium (Life Technologies
Corporation, Grand Island, NY, USA) supplemented with 10% fetal
bovine serum, 4 mM L-glutamine, and 2 mM sodium pyruvate
(R-10). RhPBMCs were prepared and cultured as described pre-
viously (Imamichi et al., 2002), with minor modiﬁcation; 160
units/ml recombinant interleukin-2 (Wako Pure Chemicals,
Osaka, Japan) was added to the medium to maintain lymphocytes.
RhAMs were collected through a bronchoalveolar lavage techni-
que and cultured as described previously (Imamichi et al., 2002).Viruses
Virus stocks of SIV239 (Kestler et al., 1988), SIV316 (Desrosiers
et al., 1991), SHIV DH12R CL7 (Sadjadpour et al., 2004), and SHIV
l3-3 (Igarashi et al., 2007) were propagated in RhPBMCs following
inoculation with transfection supernatant of the proviral plasmid
of each virus. Dr. Ronald C. Desrosiers at Harvard University kindly
provided the plasmid of SIV239. Dr. Malcolm A. Martin at the
National Institute of Allergy and Infectious Diseases (NIAID), NIH,
generously contributed the plasmid of SIV316 with permission
from Dr. Desrosiers and the plasmids of SHIV DH12R CL-7 and SHIV
l3-3. Infectious titers (TCID50) of the virus stocks were determined
by titration as described previously (Shibata et al., 1997), with a
minor modiﬁcation; the indicator cells employed for titration were
RhPBMCs in this study. The HIV-1 97ZA012 isolate was obtained
from The UNAIDS Network for HIV Isolation and Characterization
through the AIDS Research and Reference Reagent Program, Divi-
sion of AIDS, NIAID, NIH, and was propagated brieﬂy in human
PBMCs after acquisition.Preparation of cDNA from HIV-1 97ZA012 genomic RNA
Culture supernatant was harvested from human PBMCs infected
with HIV-1 97ZA012 on day 8 post-inoculation. Virion-associated
RNA was extracted with the QIAamp Viral RNA mini kit (QIAGEN,
Hilden, Germany), following the manufacturer’s instructions.
The extracted RNA was subsequently subjected to synthesis of
cDNAwith Super Script III (Life Technologies Corporation) following
the manufacturer’s instructions. For the reaction, the following
primer was utilized: OFM19-R (50-aggcaagctttattgaggctta-30 at
9604-9625 in HIV-1 HXB2).
Generation of recombinant virus through IHR
Two segments of the SHIV genome (Fragments I and II; Fig. 1)
were ampliﬁed by PCR with pSHIV KS661, an infectious molecular
clone of SHIV C2/1 (Shinohara et al., 1999), as a template. Positions
of PCR primers were numbered relative to the SIV239 or HIV-1
HXB2 genome sequence (GenBank accession nos. M33262 and
K03455, respectively). For Fragment I, the following primer pair
was employed: SIVU3Not-F forward primer (50-atgcggccgctggaagg-
gatttattacagtgcaag-30, at 1–25 in SIV239) and SHenv2R rear primer
(50-cacagagtggggttaattttacac-30, at 6580–6603 in HIV-1 HXB2). Two
sets of Fragment II (II-a and II-b) were ampliﬁed by PCR. For
Fragment II-a, the following primer pair was used: SHenv5.5F
forward primer (50-tcataatgatagtaggaggc-30, at 8278–8297 in HIV-
1 HXB2) and SIVU5Eco-R rear primer (50-tgcagaattctgctagggat-
tttcctgcttcggtt-30, at 10255–10279 in SIV239). For Fragment II-b,
the following primer pair was utilized: SHenv6F forward primer
(50-gcggagcctgtgcctcttcagc-30, at 8504–8525 in HIV-1 HXB2) and
SIVU5Eco-R rear primer. A segment of the HIV-1 97ZA012 genome
containing env and ﬂanking genes (Fragment III) was ampliﬁed
through PCR with cDNA of viral genomic RNA as a template. For
ampliﬁcation of Fragment III, the following primer pair was applied:
HIVvpr-F forward primer (50-agatggaacaagccccagaaga-30 at 5557–
5578 in HIV-1 HXB2) and OFM19-R rear primer.
All PCR reactions were conducted with the Expand Long Range
dNTPack (Roche Diagnostic Corporation, Basel, Switzerland)
under the following conditions: initial denaturation at 94 1C for
2 min, followed by 10 cycles of ampliﬁcation consisting of
denaturation at 94 1C for 15 s, annealing at 55 1C for 30 s, and
extension at 68 1C for 8 min. The reaction was continued with 25
cycles of ampliﬁcation consisting of denaturation at 94 1C for 15 s,
annealing at 55 1C for 30 s, and extension at 68 1C for 8 min (plus
20 s at every cycle), followed by a ﬁnal extension at 68 1C for
7 min.
Mixtures of Fragments I, II-a, and III (Transfection #1) or I, II-b,
and III (Transfection #2), 0.2 mg of each fragment, were co-
transfected into C8166-CCR5 cells through diethylaminoethyl-
dextran-mediated DNA uptake followed by osmotic shock (Takai
and Ohmori, 1990). After co-transfection, the cell cultures were
maintained in 24-well plates at 37 1C and monitored by daily
microscopic observation. On day 14 for Transfection #1 and day
15 for Transfection #2, a small portion of each culture was taken
and independently co-cultured with uninfected C8166-CCR5 cells
for an additional 3 days.
In vitro passage of recombinant virus
RhPBMCs were prepared as described above. The CD8þ cell
fraction was removed from the cell preparation using phycoery-
thrin (PE)-conjugated anti-CD8 antibody (clone SK1; BD BioS-
ciences, San Jose, CA, USA) and anti-PE-conjugated magnetic
microbeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany),
following the manufacturers’ instructions.
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Transfection #1 or Transfection #2 on days 17 and 18 post-
transfection, respectively, was mixed and ﬁltered through a 0.45-
mm membrane. The supernatant, 100 ml in total, was subsequently
inoculated into 2106 CD4þ cell-enriched RhPBMCs (Passage #1).
Freshly prepared CD4þ cell-enriched RhPBMCs, 2106 cells in
total, were added to Passage #1 on day 3 post-inoculation. Virus
replication was assessed by virion-associated RT activity in the
culture supernatant, as described below. Cryopreserved super-
natant on day 5 (50 ml) from Passage #1 was thawed and
inoculated into 2106 CD4þ cell-enriched RhPBMCs (Passage
#2). On day 3, freshly prepared CD4þ cell-enriched RhPBMCs,
2106 cells in total, were added to Passage #2. The RT activity of
the supernatant was monitored daily, and a small portion of
Passage #2 on day 8, when the RT activity rose substantially, was
subsequently co-cultured with 2106 freshly isolated RhPBMCs
without enrichment of CD4þ cells (Passage #3). On day 3, 2106
freshly prepared CD4þ cell-enriched RhPBMCs were added to
Passage #3. Cryopreserved supernatant from Passage #3 on day 7
(50 ml) was thawed and inoculated into 2106 freshly prepared
RhPBMCs without manipulation (Passage #4). On day 3, 2106
freshly prepared RhPBMCs without manipulation were added to
Passage #4. Cryopreserved supernatant from Passage #4 on day 5
(50 ml) was thawed and inoculated into 2106 freshly prepared
RhPBMCs without manipulation (Passage #5). Fresh RhPBMCs
without manipulation were added to Passage #5 on day 3.Reverse transcriptase assay
Virion-associated RT activity in the culture supernatant was
evaluated as described previously (Willey et al., 1988), with a
minor modiﬁcation; a-32P TTP was purchased from PerkinElmer
Inc. (Waltham, MA, USA) in this study.Genomic analysis of the recombinant virus
Virion-associated viral genomic RNA was extracted from
culture supernatant collected on day 5 of Passage #5 and reverse
transcribed, as described above. For sequencing, the bulk cDNA
was directly subjected to the Sanger dideoxy method with a
BigDye Terminator Cycle Sequencing Kit (Life Technologies
Corporation) and analyzed with an ABI PRISM 3130 Genetic
Analyzer (Life Technologies Corporation).
Breakpoints of the recombinant virus were determined
through comparison of sequences of the recombinant virus with
those of SHIV KS661 (identical to SHIV C2/1, GenBank accession
no. AF217181) and p97ZA012 (GenBank accession no. AF286227).
The sequences were aligned using Clustal X software (Thompson
et al., 1997) and analyzed using SimPlot software (Lole et al.,
1999), with a window size of 250 bp and a step size of 20 bp.
A portion of the nt sequence of SHIV 97ZA012, at nt 6429–8325
(in HIV-1 HXB2) and derived from HIV-1 97ZA012, was subjected
to phylogenetic analysis with the corresponding sequence of the
following reference virus isolates: 93IN905 (GenBank accession no.
AY669742), 98CN009 (AF286230), 98CN006 (AF286229), 98TZ017
(AF286235), 97ZA009 (AY118166), and 97ZA012 (AF286227) for
subtype C references, and DH12.3 (AF069140), JR-FL (U63632),
ADA.AD8 (AF004394), SF162 (EU123924), HXB2 (K03455), and
SHIV KS661 for subtype B references. Phylogenetic analysis by
neighbor-joining method (Saitou and Nei, 1987) was conducted
using Clustal X software. The analyzed result was plotted by Mega
5 software (Tamura et al., 2011).Replication kinetics of SHIV 97ZA012
Virus stocks subjected to comparison were normalized to the
infectious titer (MOI¼0.01 or 0.1 TCID50/cell). For infection of
M8166-CCR5 cells, HIV-1 97ZA012, SHIV KS661, and SHIV
97ZA012 were titrated using TZM-bl cells, which were granted
from the NIH AIDS Research & Reference Reagent Program. For
infection of RhPBMCs, SIV239 and SHIV 97ZA012 were titrated in
RhPBMCs. The virus stocks were inoculated to C8166-CCR5 cells
or RhPBMCs by spinoculation (O’Doherty et al., 2000) at 1200 g
for 60 min.
After inoculation, culture supernatant was replaced daily with
freshly prepared medium and stored at 20 1C until analysis of
its RT activity. The AUC of the replication kinetics, an estimate of
the total production of progeny virus during the observation
period, was calculated for each virus using the Prism 4 Software
(GraphPad Software, Inc., La Jolla, CA, USA).Co-receptor usage assay
The co-receptor preference of SHIV 97ZA012 on RhPBMCs was
analyzed as described previously (Matsuda et al., 2010), with the
modiﬁcations described below. Infectious titers of SHIV 97ZA012,
SIV239, and SHIV DH12R CL7 were normalized by the infectious
titer (MOI¼0.03 TCID50/cell) in this study. In the presence of
5 mM of the small-molecule co-receptor inhibitors AMD3100
(De Clercq et al., 1994) (Sigma-Aldrich, St. Louis, MO, USA),
AD101 (Trkola et al., 2002), or both, the viruses were spinoculated
(1200 g for 60 min) into RhPBMCs, and virus replication was
monitored for 7 days. During the experiment, culture supernatant
was replaced on days 1, 3, and 5 with freshly prepared culture
medium containing the same concentration of corresponding
inhibitor(s). Culture supernatant was collected on days 1, 3, 5,
and 7 and stored at 20 1C until assessment of RT activity.
Dr. Julie Strizki, Schering-Plough Research Institute, Kenilworth,
NJ, generously provided the AD101.Replication of SHIV 97ZA012 in RhAMs
RhAMs were collected and cultured as described above. SHIV
97ZA012, SIV239, SIV316, and SHIV l3-3 were normalized by RT
activity (MOI¼17 cpm equivalent/cell) and spinoculated
(1200 g for 60 min) to 5105 cells in a 24-well plate. Culture
supernatant was replaced every other day with freshly prepared
medium and stored at 20 1C until assessment of its RT activity.Experimental infection of rhesus monkeys with SHIV 97ZA012
Rhesus macaques of Indian origin, approximately 4 kg in body
weight, were used for experimental infection with SHIV 97ZA012.
Phlebotomy, bronchoalveolar lavage, lymph node biopsy, and virus
inoculation were conducted under anesthesia by intramuscular
injection of a mixture of ketamine chloride (Ketalar; Daiichi
Sankyo, Tokyo, Japan) at 5–10 mg/kg and xylazine chloride
(Celactal; Bayer Healthcare, Leverkusen, Germany) at 1.5–2.0 mg/
kg. Animals 533, 535, and 536 were intravenously inoculated with
1105 TCID50 SHIV 97ZA012. Animal 554 intravenously received a
mixture of anticoagulated whole blood (10 ml) and lymph node
cells (5108 cells) collected from animals 535 and 536 at 10.7
weeks post-inoculation. All animal experiments were conducted in
a biosafety level 3 animal facility in compliance with institutional
regulations approved by the Committee for Experimental Use of
Nonhuman Primates of the Institute for Virus Research, Kyoto
University, Kyoto, Japan.
Y. Fujita et al. / Virology 436 (2013) 100–111110Acknowledgments
The authors thank Drs. Julie Strizki and Paul Zavodny for
providing AD101, the NIH AIDS Research & Reference Reagent
Program for providing primary isolates of HIV-1 and TZM-bl cells,
Dr. A. Nomoto for continuous support, and members of the
Igarashi laboratory for assistance with animal procedures and
analyses. This work was supported by a Research on HIV/AIDS
grant [awarded to T.M. and T.I., independently] from The Ministry
of Health, Labor and Welfare of Japan, and by a Grant-in-Aid for
Scientiﬁc Research (B) [awarded to T.M. and T.I., independently]
from the Japan Society for the Promotion of Science.
References
Brenchley, J.M., Schacker, T.W., Ruff, L.E., Price, D.A., Taylor, J.H., Beilman, G.J.,
Nguyen, P.L., Khoruts, A., Larson, M., Haase, A.T., Douek, D.C., 2004. CD4þ T
cell depletion during all stages of HIV disease occurs predominantly in the
gastrointestinal tract. J. Exp. Med. 200, 749–759.
Broder, C.C., Jones-Trower, A., 1999. Coreceptor Use by Primate Lentiviruses,
Human Retroviruses and AIDS. Theoretical Biology and Biophysics Group.
Los Alamos National Laboratory, Los Alamos, NM.
Carr, J.K., Avila, M., Gomez Carrillo, M., Salomon, H., Hierholzer, J., Watanaveeradej, V.,
Pando, M.A., Negrete, M., Russell, K.L., Sanchez, J., Birx, D.L., Andrade, R., Vinoles, J.,
McCutchan, F.E., 2001. Diverse BF recombinants have spread widely since the
introduction of HIV-1 into South America. Aids 15, F41–47.
Chen, Z., Huang, Y., Zhao, X., Skulsky, E., Lin, D., Ip, J., Gettie, A., Ho, D.D., 2000.
Enhanced infectivity of an R5-tropic simian/human immunodeﬁciency virus
carrying human immunodeﬁciency virus type 1 subtype C envelope after
serial passages in pig-tailed macaques (Macaca nemestrina). J. Virol. 74,
6501–6510.
Cheng-Mayer, C., Quiroga, M., Tung, J.W., Dina, D., Levy, J.A., 1990. Viral determi-
nants of human immunodeﬁciency virus type 1 T-cell or macrophage tropism,
cytopathogenicity, and CD4 antigen modulation. J. Virol. 64, 4390–4398.
Clavel, F., Hoggan, M.D., Willey, R.L., Strebel, K., Martin, M.A., Repaske, R., 1989.
Genetic recombination of human immunodeﬁciency virus. J. Virol. 63,
1455–1459.
De Clercq, E., Yamamoto, N., Pauwels, R., Balzarini, J., Witvrouw, M., De Vreese, K.,
Debyser, Z., Rosenwirth, B., Peichl, P., Datema, R., et al., 1994. Highly potent
and selective inhibition of human immunodeﬁciency virus by the bicyclam
derivative JM3100. Antimicrob. Agents Chemother. 38, 668–674.
Desrosiers, R.C., Hansen-Moosa, A., Mori, K., Bouvier, D.P., King, N.W., Daniel, M.D.,
Ringler, D.J., 1991. Macrophage-tropic variants of SIV are associated with
speciﬁc AIDS-related lesions but are not essential for the development of AIDS.
Am. J. Pathol. 139, 29–35.
DuBridge, R.B., Tang, P., Hsia, H.C., Leong, P.M., Miller, J.H., Calos, M.P., 1987.
Analysis of mutation in human cells by using an Epstein-Barr virus shuttle
system. Mol. Cell. Biol. 7, 379–387.
Gorry, P.R., Bristol, G., Zack, J.A., Ritola, K., Swanstrom, R., Birch, C.J., Bell, J.E.,
Bannert, N., Crawford, K., Wang, H., Schols, D., De Clercq, E., Kunstman, K.,
Wolinsky, S.M., Gabuzda, D., 2001. Macrophage tropism of human immuno-
deﬁciency virus type 1 isolates from brain and lymphoid tissues predicts
neurotropism independent of coreceptor speciﬁcity. J. Virol. 75, 10073–10089.
Guimaraes, M.L., Eyer-Silva, W.A., Couto-Fernandez, J.C., Morgado, M.G., 2008.
Identiﬁcation of two new CRF_BF in Rio de Janeiro State, Brazil. Aids 22,
433–435.
Harouse, J.M., Gettie, A., Eshetu, T., Tan, R.C., Bohm, R., Blanchard, J., Baskin, G.,
ChengMayer, C., 2001. Mucosal transmission and induction of simian AIDS by
CCR5-speciﬁc simian/human immunodeﬁciency virus SHIV(SF162P3). J. Virol.
75, 1990–1995.
Hemelaar, J., Gouws, E., Ghys, P.D., Osmanov, S., 2011. Global trends in molecular
epidemiology of HIV-1 during 2000-2007. Aids 25, 679–689.
Hertogs, K., de Bethune, M.P., Miller, V., Ivens, T., Schel, P., Van Cauwenberge, A.,
Van Den Eynde, C., Van Gerwen, V., Azijn, H., Van Houtte, M., Peeters, F.,
Staszewski, S., Conant, M., Bloor, S., Kemp, S., Larder, B., Pauwels, R., 1998. A
rapid method for simultaneous detection of phenotypic resistance to inhibi-
tors of protease and reverse transcriptase in recombinant human immunode-
ﬁciency virus type 1 isolates from patients treated with antiretroviral drugs.
Antimicrob. Agents Chemother. 42, 269–276.
Hirsch, V., Adger-Johnson, D., Campbell, B., Goldstein, S., Brown, C., Elkins, W.R.,
Monteﬁori, D.C., 1997. A molecularly cloned, pathogenic, neutralization-
resistant simian immunodeﬁciency virus, SIVsmE543-3. J. Virol. 71,
1608–1620.
Igarashi, T., Endo, Y., Englund, G., Sadjadpour, R., Matano, T., Buckler, C., Buckler-
White, A., Plishka, R., Theodore, T., Shibata, R., Martin, M., 1999. Emergence of
a highly pathogenic simian/human immunodeﬁciency virus in a rhesus
macaque treated with anti-CD8 mAb during a primary infection with a
nonpathogenic virus. Proc. Natl. Acad. Sci. USA 96, 14049–14054.
Igarashi, T., Donau, O.K., Imamichi, H., Nishimura, Y., Theodore, T.S., Iyengar, R.,
Erb, C., Buckler-White, A., Buckler, C.E., Martin, M.A., 2007. Although
macrophage-tropic simian/human immunodeﬁciency viruses can exhibit arange of pathogenic phenotypes, a majority of isolates induce no clinical
disease in immunocompetent macaques. J. Virol. 81, 10669–10679.
Igarashi, T., Donau, O.K., Matsuyama, M., Unpublished Results.
Imamichi, H., Igarashi, T., Imamichi, T., Donau, O.K., Endo, Y., Nishimura, Y.,
Willey, R.L., Suffredini, A.F., Lane, H.C., Martin, M.A., 2002. Amino acid deletions
are introduced into the V2 region of gp120 during independent pathogenic
simian immunodeﬁciency virus/HIV chimeric virus (SHIV) infections of rhesus
monkeys generating variants that are macrophage tropic. Proc. Natl. Acad. Sci.
USA 99, 13813–13818.
Inoue, M., Hoxie, J.A., Reddy, M.V., Srinivasan, A., Reddy, E.P., 1991. Mechanisms
associated with the generation of biologically active human immunodeﬁ-
ciency virus type 1 particles from defective proviruses. Proc. Natl. Acad. Sci.
USA 88, 2278–2282.
Joag, S.V., Li, Z., Foresman, L., Stephens, E.B., Zhao, L.J., Adany, I., Pinson, D.M.,
McClure, H.M., Narayan, O., 1996. Chimeric simian/human immunodeﬁciency
virus that causes progressive loss of CD4þ T cells and AIDS in pig-tailed
macaques. J. Virol. 70, 3189–3197.
John-Stewart, G.C., Nduati, R.W., Rousseau, C.M., Mbori-Ngacha, D.A., Richardson, B.A.,
Rainwater, S., Panteleeff, D.D., Overbaugh, J., 2005. Subtype C is associated with
increased vaginal shedding of HIV-1. J. Infect. Dis. 192, 492–496.
Kalyanaraman, S., Jannoun-Nasr, R., York, D., Luciw, P.A., Robinson, R., Srinivasan, A.,
1988. Homologous recombination between human immunodeﬁciency viral
DNAs in cultured human cells: analysis of the factors inﬂuencing recombination.
Biochem. Biophys. Res. Commun. 157, 1051–1060.
Kamada, K., Igarashi, T., Martin, M.A., Khamsri, B., Hatcho, K., Yamashita, T.,
Fujita, M., Uchiyama, T., Adachi, A., 2006. Generation of HIV-1 derivatives that
productively infect macaque monkey lymphoid cells. Proc. Natl. Acad. Sci. USA
103, 16959–16964.
Kellam, P., Larder, B.A., 1994. Recombinant virus assay: a rapid, phenotypic assay
for assessment of drug susceptibility of human immunodeﬁciency virus type
1 isolates. Antimicrob. Agents Chemother. 38, 23–30.
Kestler 3rd, H.W., Li, Y., Naidu, Y.M., Butler, C.V., Ochs, M.F., Jaenel, G., King, N.W.,
Daniel, M.D., Desrosiers, R.C., 1988. Comparison of simian immunodeﬁciency
virus isolates. Nature 331, 619–622.
Koulinska, I.N., Ndung’u, T., Mwakagile, D., Msamanga, G., Kagoma, C., Fawzi, W.,
Essex, M., Renjifo, B., 2001. A new human immunodeﬁciency virus type
1 circulating recombinant form from Tanzania. AIDS Res. Hum. Retroviruses
17, 423–431.
Kuwata, T., Takemura, T., Takehisa, J., Miura, T., Hayami, M., 2002. Infection of
macaques with chimeric simian and human immunodeﬁciency viruses con-
taining Env from subtype F. Arch. Virol. 147, 1121–1132.
Li, J., Lord, C.I., Haseltine, W., Letvin, N.L., Sodroski, J., 1992. Infection of cynomolgus
monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1
envelope glycoproteins. J. Acquired Immune Deﬁc. Syndromes 5, 639–646.
Lole, K.S., Bollinger, R.C., Paranjape, R.S., Gadkari, D., Kulkarni, S.S., Novak, N.G.,
Ingersoll, R., Sheppard, H.W., Ray, S.C., 1999. Full-length human immunode-
ﬁciency virus type 1 genomes from subtype C-infected seroconverters in India,
with evidence of intersubtype recombination. J. Virol. 73, 152–160.
Luciw, P.A., Pratt-Lowe, E., Shaw, K.E., Levy, J.A., Cheng-Mayer, C., 1995. Persistent
infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic
clones of simian/human immunodeﬁciency viruses (SHIV). Proc. Natl. Acad.
Sci. USA 92, 7490–7494.
Mao, Z., Jiang, Y., Liu, X., Seluanov, A., Gorbunova, V., 2009. DNA repair by
homologous recombination, but not by nonhomologous end joining, is
elevated in breast cancer cells. Neoplasia 11, 683–691.
Matsuda, K., Inaba, K., Fukazawa, Y., Matsuyama, M., Ibuki, K., Horiike, M., Saito, N.,
Hayami, M., Igarashi, T., Miura, T., 2010. In vivo analysis of a new R5 tropic
SHIV generated from the highly pathogenic SHIV-KS661, a derivative of SHIV-
89.6. Virology 399, 134–143.
Miller, C.J., Marthas, M., Greenier, J., Lu, D., Dailey, P.J., Lu, Y., 1998. In vivo
replication capacity rather than in vitro macrophage tropism predicts efﬁ-
ciency of vaginal transmission of simian immunodeﬁciency virus or simian/
human immunodeﬁciency virus in rhesus macaques. J. Virol. 72, 3248–3258.
Moore, P.L., Gray, E.S., Choge, I.A., Ranchobe, N., Mlisana, K., Abdool Karim, S.S.,
Williamson, C., Morris, L., 2008. The c3-v4 region is a major target of
autologous neutralizing antibodies in human immunodeﬁciency virus type
1 subtype C infection. J. Virol. 82, 1860–1869.
Mori, K., Ringler, D.J., Desrosiers, R.C., 1993. Restricted replication of simian
immunodeﬁciency virus strain 239 in macrophages is determined by env
but is not due to restricted entry. J. Virol. 67, 2807–2814.
Mori, K., Rosenzweig, M., Desrosiers, R.C., 2000. Mechanisms for adaptation of
simian immunodeﬁciency virus to replication in alveolar macrophages. J. Virol.
74, 10852–10859.
Ng, O.T., Eyzaguirre, L.M., Carr, J.K., Chew, K.K., Lin, L., Chua, A., Leo, Y.S., Redd, A.D.,
Quinn, T.C., Laeyendecker, O., 2012. Identiﬁcation of new CRF51_01B in
Singapore using full genome analysis of three HIV type 1 isolates. AIDS Res.
Hum. Retroviruses 28, 527–530.
Nishimura, Y., Shingai, M., Willey, R., Sadjadpour, R., Lee, W.R., Brown, C.R.,
Brenchley, J.M., Buckler-White, A., Petros, R., Eckhaus, M., Hoffman, V.,
Igarashi, T., Martin, M.A., 2010. Generation of the pathogenic R5-tropic
simian/human immunodeﬁciency virus SHIVAD8 by serial passaging in rhesus
macaques. J. Virol. 84, 4769–4781.
O’Doherty, U., Swiggard, W.J., Malim, M.H., 2000. Human immunodeﬁciency virus
type 1 spinoculation enhances infection through virus binding. J. Virol. 74,
10074–10080.
Y. Fujita et al. / Virology 436 (2013) 100–111 111Okoye, A., Meier-Schellersheim, M., Brenchley, J.M., Hagen, S.I., Walker, J.M.,
Rohankhedkar, M., Lum, R., Edgar, J.B., Planer, S.L., Legasse, A., Sylwester, A.W.,
Piatak Jr., M., Lifson, J.D., Maino, V.C., Sodora, D.L., Douek, D.C., Axthelm, M.K.,
Grossman, Z., Picker, L.J., 2007. Progressive CD4þ central memory T cell decline
results in CD4þ effector memory insufﬁciency and overt disease in chronic SIV
infection. The Journal of experimental medicine 204, 2171–2185.
Perez, L., Thomson, M.M., Bleda, M.J., Aragones, C., Gonzalez, Z., Perez, J., Sierra, M.,
Casado, G., Delgado, E., Najera, R., 2006. HIV Type 1 molecular epidemiology in
cuba: high genetic diversity, frequent mosaicism, and recent expansion of BG
intersubtype recombinant forms. AIDS Res. Hum. Retroviruses 22, 724–733.
Piyasirisilp, S., McCutchan, F.E., Carr, J.K., Sanders-Buell, E., Liu, W., Chen, J.,
Wagner, R., Wolf, H., Shao, Y., Lai, S., Beyrer, C., Yu, X.F., 2000. A recent
outbreak of human immunodeﬁciency virus type 1 infection in southern China
was initiated by two highly homogeneous, geographically separated strains,
circulating recombinant form AE and a novel BC recombinant. J. Virol. 74,
11286–11295.
Puffer, B.A., Pohlmann, S., Edinger, A.L., Carlin, D., Sanchez, M.D., Reitter, J.,
Watry, D.D., Fox, H.S., Desrosiers, R.C., Doms, R.W., 2002. CD4 independence
of simian immunodeﬁciency virus Envs is associated with macrophage tropism,
neutralization sensitivity, and attenuated pathogenicity. J. Virol. 76, 2595–2605.
Reimann, K.A., Li, J.T., Veazey, R., Halloran, M., Park, I.W., Karlsson, G.B., Sodroski, J.,
Letvin, N.L., 1996a. A chimeric simian/human immunodeﬁciency virus expres-
sing a primary patient human immunodeﬁciency virus type 1 isolate env
causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol.
70, 6922–6928.
Reimann, K.A., Li, J.T., Voss, G., Lekutis, C., TennerRacz, K., Racz, P., Lin, W.,
Monteﬁori, D.C., LeeParritz, D.E., Lu, Y., Collman, R.G., Sodroski, J., Letvin,
N.L., 1996b. An env gene derived from a primary human immunodeﬁciency
virus type 1 isolate confers high in vivo replicative capacity to a chimeric
simian/human immunodeﬁciency virus in rhesus monkeys. J. Virol. 70,
3198–3206.
Sadjadpour, R., Theodore, T.S., Igarashi, T., Donau, O.K., Plishka, R.J., Buckler-White, A.,
Martin, M.A., 2004. Induction of disease by a molecularly cloned highly
pathogenic simian immunodeﬁciency virus/human immunodeﬁciency virus
chimera is multigenic. J. Virol. 78, 5513–5519.
Saitou, N., Nei, M., 1987. The neighbor-joining method: a new method for
reconstructing phylogenetic trees. Mol. Biol. Evol. 4, 406–425.
Sakuragi, S., Shibata, R., Mukai, R., Komatsu, T., Fukasawa, M., Sakai, H., Sakuragi, J.,
Kawamura, M., Ibuki, K., Hayami, M., 1992. Infection of macaque monkeys
with a chimeric human and simian immunodeﬁciency virus. J. Gen. Virol. 73
(Pt 11), 2983–2987.
Sharma, D.P., Zink, M.C., Anderson, M., Adams, R., Clements, J.E., Joag, S.V., Narayan, O.,
1992. Derivation of neurotropic simian immunodeﬁciency virus from exclusively
lymphocytetropic parental virus: pathogenesis of infection in macaques. J. Virol.
66, 3550–3556.
Shibata, R., Kawamura, M., Sakai, H., Hayami, M., Ishimoto, A., Adachi, A., 1991.
Generation of a chimeric human and simian immunodeﬁciency virus infec-
tious to monkey peripheral blood mononuclear cells. J. Virol. 65, 3514–3520.
Shibata, R., Maldarelli, F., Siemon, C., Matano, T., Parta, M., Miller, G., Fredrickson,
T., Martin, M.A., 1997. Infection and pathogenicity of chimeric simian-human
immunodeﬁciency viruses in macaques: determinants of high virus loads and
CD4 cell killing. J. Infect. Dis. 176, 362–373.
Shinohara, K., Sakai, K., Ando, S., Ami, Y., Yoshino, N., Takahashi, E., Someya, K.,
Suzaki, Y., Nakasone, T., Sasaki, Y., Kaizu, M., Lu, Y., Honda, M., 1999. A highly
pathogenic simian/human immunodeﬁciency virus with genetic changes in
cynomolgus monkey. J. Gen. Virol. 80 (Pt 5), 1231–1240.
Soda, Y., Shimizu, N., Jinno, A., Liu, H.Y., Kanbe, K., Kitamura, T., Hoshino, H., 1999.
Establishment of a new system for determination of coreceptor usages of HIV
based on the human glioma NP-2 cell line. Biochem. Biophys. Res. Commun.
258, 313–321.Song, R.J., Chenine, A.L., Rasmussen, R.A., Ruprecht, C.R., Mirshahidi, S., Grisson,
R.D., Xu, W., Whitney, J.B., Goins, L.M., Ong, H., Li, P.L., ShaiKobiler, E., Wang, T.,
McCann, C.M., Zhang, H., Wood, C., Kankasa, C., Secor, W.E., McClure, H.M.,
Strobert, E., Else, J.G., Ruprecht, R.M., 2006. Molecularly cloned SHIV-
1157ipd3N4: a highly replication–competent, mucosally transmissible R5
simian-human immunodeﬁciency virus encoding HIV clade C Env. J. Virol.
80, 8729–8739.
Srinivasan, A., York, D., Jannoun-Nasr, R., Kalyanaraman, S., Swan, D., Benson, J.,
Bohan, C., Luciw, P.A., Schnoll, S., Robinson, R.A., et al., 1989. Generation of
hybrid human immunodeﬁciency virus by homologous recombination. Proc.
Natl. Acad. Sci. USA 86, 6388–6392.
Su, L., Graf, M., Zhang, Y., von Briesen, H., Xing, H., Kostler, J., Melzl, H., Wolf, H.,
Shao, Y., Wagner, R., 2000. Characterization of a virtually full-length human
immunodeﬁciency virus type 1 genome of a prevalent intersubtype (C/B’)
recombinant strain in China. J. Virol. 74, 11367–11376.
Takai, T., Ohmori, H., 1990. DNA transfection of mouse lymphoid cells by the
combination of DEAE-dextran-mediated DNA uptake and osmotic shock
procedure. Biochim. Biophys. Acta 1048, 105–109.
Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M., Kumar, S., 2011. MEGA5:
molecular evolutionary genetics analysis using maximum likelihood, evolution-
ary distance, and maximum parsimony methods. Mol. Biol. Evol. 28, 2731–2739.
Thompson, J.D., Gibson, T.J., Plewniak, F., Jeanmougin, F., Higgins, D.G., 1997. The
CLUSTAL_X windows interface: ﬂexible strategies for multiple sequence
alignment aided by quality analysis tools. Nucl. Acids Res. 25, 4876–4882.
Trkola, A., Kuhmann, S.E., Strizki, J.M., Maxwell, E., Ketas, T., Morgan, T., Pugach, P.,
Xu, S., Wojcik, L., Tagat, J., Palani, A., Shapiro, S., Clader, J.W., McCombie, S.,
Reyes, G.R., Baroudy, B.M., Moore, J.P., 2002. HIV-1 escape from a small
molecule, CCR5-speciﬁc entry inhibitor does not involve CXCR4 use. Proc.
Natl Acad. Sci. USA 99, 395–400.
UNAIDS, 2010. Report on the Global Aids Epidemic.
Veazey, R.S., DeMaria, M., Chalifoux, L.V., Shvetz, D.E., Pauley, D.R., Knight, H.L.,
Rosenzweig, M., Johnson, R.P., Desrosiers, R.C., Lackner, A.A., 1998. Gastro-
intestinal tract as a major site of CD4þ T cell depletion and viral replication in
SIV infection. Science 280, 427–431.
Veazey, R.S., Marx, P.A., Lackner, A.A., 2003. Vaginal CD4þ T cells express high
levels of CCR5 and are rapidly depleted in simian immunodeﬁciency virus
infection. J. Infect. Dis. 187, 769–776.
Vispe, S., Cazaux, C., Lesca, C., Defais, M., 1998. Overexpression of Rad51 protein
stimulates homologous recombination and increases resistance of mammalian
cells to ionizing radiation. Nucl. Acids Res. 26, 2859–2864.
Walter, B.L., Armitage, A.E., Graham, S.C., de Oliveira, T., Skinhoj, P., Jones, E.Y.,
Stuart, D.I., McMichael, A.J., Chesebro, B., Iversen, A.K., 2009. Functional
characteristics of HIV-1 subtype C compatible with increased heterosexual
transmissibility. Aids 23, 1047–1057.
Willey, R.L., Smith, D.H., Lasky, L.A., Theodore, T.S., Earl, P.L., Moss, B., Capon, D.J.,
Martin, M.A., 1988. In vitro mutagenesis identiﬁes a region within the
envelope gene of the human immunodeﬁciency virus that is critical for
infectivity. J. Virol. 62, 139–147.
Worgall, S., Connor, R., Kaner, R.J., Fenamore, E., Sheridan, K., Singh, R., Crystal, R.G.,
1999. Expression and use of human immunodeﬁciency virus type 1 coreceptors
by human alveolar macrophages. J. Virol. 73, 5865–5874.
Yamaguchi, J., Badreddine, S., Swanson, P., Bodelle, P., Devare, S.G., Brennan, C.A.,
2008. Identiﬁcation of new CRF43_02G and CRF25_cpx in Saudi Arabia based
on full genome sequence analysis of six HIV type 1 isolates. AIDS Res. Hum.
Retroviruses 24, 1327–1335.
Zhang, Y., Lou, B., Lal, R.B., Gettie, A., Marx, P.A., Moore, J.P., 2000. Use of inhibitors
to evaluate coreceptor usage by simian and simian/human immunodeﬁciency
viruses and human immunodeﬁciency virus type 2 in primary cells. J. Virol. 74,
6893–6910.
